CD8A and neoplasm: These data suggest that this personalized DC vaccine approach can bolster anti-tumor immune responses through two potential mechanisms: the induction of antigen-specific CD8+ T cells targeting neoantigens pulsed in the DC vaccine and the generation of new antigen-specific CD8+ T cells with TCR specificity against previously untargeted cancer epitopes.